SAB Biotherapeutics Revenue and Competitors

Sioux Falls,

Location

$40.4M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • SAB Biotherapeutics's estimated annual revenue is currently $6.4M per year.(i)
  • SAB Biotherapeutics's estimated revenue per employee is $100,500
  • SAB Biotherapeutics's total funding is $40.4M.

Employee Data

  • SAB Biotherapeutics has 64 Employees.(i)
  • SAB Biotherapeutics grew their employee count by 7% last year.

SAB Biotherapeutics's People

NameTitleEmail/Phone
1
Co-Founder, Executive ChairmanReveal Email/Phone
2
Chief Corporate Communications & Investor Relations OfficerReveal Email/Phone
3
SVP, Research and Product DevelopmentReveal Email/Phone
4
VP, Clinical OperationsReveal Email/Phone
5
ControllerReveal Email/Phone
6
EVP & Chief Operating OfficerReveal Email/Phone
7
DirectorReveal Email/Phone
8
Executive Director, Animal ManagementReveal Email/Phone
9
Executive Director Molecular Genetics & ImmunologyReveal Email/Phone
10
Senior Director Regulatory AffairsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is SAB Biotherapeutics?

SAB Biotherapeutics is a clinical-stage biopharmaceutical development company using its novel immunotherapy platform to produce life-saving therapies.

keywords:N/A

$40.4M

Total Funding

64

Number of Employees

$6.4M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

SAB Biotherapeutics News

2022-04-06 - Analyst Rating: Will SAB Biotherapeutics Inc (SABS) Stock Lead the Market?

That average rating earns SAB Biotherapeutics Inc an Analyst Ranking of 73, which means it ranks higher than 73 of stocks, based on data...

2022-04-06 - SAB releases year-end earnings, company update

Sioux Falls-based SAB Biotherapeutics provided updates on its therapeutics for COVID-19, influenza and type 1 diabetes in reporting its...

2022-03-30 - SAB Biotherapeutics Provides Company Update and Reports ...

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human...

2020-07-18 - SAB Biotherapeutics Raises $14M in Series B Funding

SAB Biotherapeutics, a Sioux Falls, S.D.-based clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human plasma donors, closed a $14m Series B funding round. New investor, global healthcare leader Merck, known ...

2020-01-07 - SAB Biotherapeutics Announces Research Collaboration With CSL Behring

SIOUX FALLS, S.D.–(BUSINESS WIRE)–January 7, 2020– SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, today announced that it has entered into multiple collaboration and option agreements with global biotherapeutics leader ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.1M642%N/A
#2
$18.5M645%N/A
#3
$8.2M65-10%N/A
#4
$12M65-3%N/A
#5
$17.2M668%N/A